Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging - PubMed (original) (raw)
. 2003 Aug;50(2):293-302.
doi: 10.1002/mrm.10529.
Einar M Sigurdsson, Marcin Sadowski, James I Elliott, Yongsheng Li, Henrieta Scholtzova, Cheuk Ying Tang, Gilbert Aguinaldo, Miguel Pappolla, Karen Duff, Thomas Wisniewski, Daniel H Turnbull
Affiliations
- PMID: 12876705
- DOI: 10.1002/mrm.10529
Free article
Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging
Youssef Zaim Wadghiri et al. Magn Reson Med. 2003 Aug.
Free article
Abstract
The presence of amyloid-beta (Abeta) plaques in the brain is a hallmark pathological feature of Alzheimer's disease (AD). Transgenic mice overexpressing mutant amyloid precursor protein (APP), or both mutant APP and presenilin-1 (APP/PS1), develop Abeta plaques similar to those in AD patients, and have been proposed as animal models in which to test experimental therapeutic approaches for the clearance of Abeta. However, at present there is no in vivo whole-brain imaging method to detect Abeta plaques in mice or men. A novel method is presented to detect Abeta plaques in the brains of transgenic mice by magnetic resonance microimaging (muMRI). This method uses Abeta1-40 peptide, known for its high binding affinity to Abeta, magnetically labeled with either gadolinium (Gd) or monocrystalline iron oxide nanoparticles (MION). Intraarterial injection of magnetically labeled Abeta1-40, with mannitol to transiently open the blood-brain barrier (BBB), enabled the detection of many Abeta plaques. Furthermore, the numerical density of Abeta plaques detected by muMRI and by immunohistochemistry showed excellent correlation. This approach provides an in vivo method to detect Abeta in AD transgenic mice, and suggests that diagnostic MRI methods to detect Abeta in AD patients may ultimately be feasible.
Copyright 2003 Wiley-Liss, Inc.
Similar articles
- Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's disease transgenic mice.
Kandimalla KK, Wengenack TM, Curran GL, Gilles EJ, Poduslo JF. Kandimalla KK, et al. J Pharmacol Exp Ther. 2007 Aug;322(2):541-9. doi: 10.1124/jpet.107.119883. Epub 2007 May 15. J Pharmacol Exp Ther. 2007. PMID: 17505020 - Detection of Aβ plaques by a novel specific MRI probe precursor CR-BSA-(Gd-DTPA)n in APP/PS1 transgenic mice.
Li S, He H, Cui W, Gu B, Li J, Qi Z, Zhou G, Liang CM, Feng XY. Li S, et al. Anat Rec (Hoboken). 2010 Dec;293(12):2136-43. doi: 10.1002/ar.21209. Anat Rec (Hoboken). 2010. PMID: 21089051 - Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability, and in vivo targeting to Alzheimer's disease amyloid plaques.
Poduslo JF, Curran GL, Peterson JA, McCormick DJ, Fauq AH, Khan MA, Wengenack TM. Poduslo JF, et al. Biochemistry. 2004 May 25;43(20):6064-75. doi: 10.1021/bi0359574. Biochemistry. 2004. PMID: 15147190 Free PMC article. - Alzheimer's disease.
De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV. De-Paula VJ, et al. Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Subcell Biochem. 2012. PMID: 23225010 Review. - Alzheimer's disease and amyloid: culprit or coincidence?
Skaper SD. Skaper SD. Int Rev Neurobiol. 2012;102:277-316. doi: 10.1016/B978-0-12-386986-9.00011-9. Int Rev Neurobiol. 2012. PMID: 22748834 Review.
Cited by
- Alzheimer's disease biomarkers in animal models: closing the translational gap.
Sabbagh JJ, Kinney JW, Cummings JL. Sabbagh JJ, et al. Am J Neurodegener Dis. 2013 Jun 21;2(2):108-20. Print 2013. Am J Neurodegener Dis. 2013. PMID: 23844335 Free PMC article. - Turn-on chemiluminescence probes and dual-amplification of signal for detection of amyloid beta species in vivo.
Yang J, Yin W, Van R, Yin K, Wang P, Zheng C, Zhu B, Ran K, Zhang C, Kumar M, Shao Y, Ran C. Yang J, et al. Nat Commun. 2020 Aug 13;11(1):4052. doi: 10.1038/s41467-020-17783-4. Nat Commun. 2020. PMID: 32792510 Free PMC article. - Dynamic study of blood-brain barrier closure after its disruption using ultrasound: a quantitative analysis.
Marty B, Larrat B, Van Landeghem M, Robic C, Robert P, Port M, Le Bihan D, Pernot M, Tanter M, Lethimonnier F, Mériaux S. Marty B, et al. J Cereb Blood Flow Metab. 2012 Oct;32(10):1948-58. doi: 10.1038/jcbfm.2012.100. Epub 2012 Jul 18. J Cereb Blood Flow Metab. 2012. PMID: 22805875 Free PMC article. - A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice.
Sigurdsson EM, Wadghiri YZ, Mosconi L, Blind JA, Knudsen E, Asuni A, Scholtzova H, Tsui WH, Li Y, Sadowski M, Turnbull DH, de Leon MJ, Wisniewski T. Sigurdsson EM, et al. Neurobiol Aging. 2008 Jun;29(6):836-47. doi: 10.1016/j.neurobiolaging.2006.12.018. Epub 2007 Feb 8. Neurobiol Aging. 2008. PMID: 17291630 Free PMC article. - In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer's transgenic mice.
Jack CR Jr, Wengenack TM, Reyes DA, Garwood M, Curran GL, Borowski BJ, Lin J, Preboske GM, Holasek SS, Adriany G, Poduslo JF. Jack CR Jr, et al. J Neurosci. 2005 Oct 26;25(43):10041-8. doi: 10.1523/JNEUROSCI.2588-05.2005. J Neurosci. 2005. PMID: 16251453 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
- R01 AG020197/AG/NIA NIH HHS/United States
- AG17617/AG/NIA NIH HHS/United States
- NS38461/NS/NINDS NIH HHS/United States
- AG15408/AG/NIA NIH HHS/United States
- AG20245/AG/NIA NIH HHS/United States
- GM57467/GM/NIGMS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical